BREAKING:

Lonza's Half-Year Results for 2025 highlight a period of strong financial and operational performance, with an optimistic revised outlook for its core Contract Development and Manufacturing Organisation (CDMO) business. The company is actively implementing a new, streamlined operating model that became effective in April 2025, impacting how its diverse business areas are structured and reported.

• Discover how Lonza's CDMO business showcased impressive growth, leading to an upward revision of its outlook for the remainder of 2025
• Uncover the recovery trajectory of the Capsules & Health Ingredients business, which is progressing as anticipated despite the ongoing preparations for its strategic exit
• Explore the varied performance across Lonza's newly formed Integrated Biologics, Advanced Synthesis, and Specialized Modalities platforms, with some areas achieving significant advancements while others navigated temporary challenges

There will be an AGM on

Event dates:

For more information, click here: LONZA GROUP LTD 2024 AGM

There will be an AGM on

Event dates:

For more information, click here: LONZA GROUP LTD 2023 AGM